Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
V. Yu. Skryabin, M. A. Vinnikova, E. V. Ezhkova, M. S. Titkov & R. A. Bulatova. (2021) Atypical antipsychotics in the treatment of patients with a dual diagnosis of schizophrenia spectrum disorders and substance use disorders: the results of a randomized comparative study. Journal of Addictive Diseases 39:4, pages 513-525.
Read now
Read now
Michael Soyka & Christian A. Müller. (2017) Pharmacotherapy of alcoholism – an update on approved and off-label medications. Expert Opinion on Pharmacotherapy 18:12, pages 1187-1199.
Read now
Read now
Michael Soyka, Henry R. Kranzler, Victor Hesselbrock, Siegfried Kasper, Jochen Mutschler & Hans-Jürgen Möller. (2017) Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision. The World Journal of Biological Psychiatry 18:2, pages 86-119.
Read now
Read now
Heidi J. Wehring, Stephen J. Heishman, Robert P. McMahon, Fang Liu, Stephanie Feldman, Heather Raley, Elaine Weiner & Deanna L. Kelly. (2017) Antipsychotic Treatment and Tobacco Craving in People With Schizophrenia. Journal of Dual Diagnosis 13:1, pages 36-42.
Read now
Read now
Articles from other publishers (28)
Sabine Hellwig & Katharina Domschke. (2023) Angst- und Abhängigkeitserkrankungen – Fokus Alkohol und CannabisAnxiety and substance abuse disorders—Focus on alcohol and cannabis. Der Nervenarzt 94:7, pages 647-654.
Crossref
Crossref
Stefania Chiappini, Alessio Mosca, Andrea Miuli, Francesco Di Carlo, Giacomo d'Andrea, Alessandra Napolitano, Monica Santangelo, Corradina Esposito, Anna Rosazza, Elena Haefele, Gilberto Di Petta, Mauro Pettorruso, Stefano L. Sensi & Giovanni Martinotti. (2023) Aripiprazole once monthly as a maintenance treatment for patients with schizophrenia and alcohol/substance use disorder: an observational, real-world study. Advances in Dual Diagnosis.
Crossref
Crossref
Marco Carli, Francesco Weiss, Giovanna Grenno, Sergio Ponzini, Shivakumar Kolachalam, Francesca Vaglini, Cristina Viaggi, Carla Pardini, Simone Tidona, Biancamaria Longoni, Roberto Maggio & Marco Scarselli. (2023) Pharmacological Strategies for Bipolar Disorders in Acute Phases and
Chronic Management with a Special Focus on Lithium, Valproic Acid, and
Atypical Antipsychotics. Current Neuropharmacology 21:4, pages 935-950.
Crossref
Crossref
Milan D. Valyear, Mandy R. LeCocq, Alexa Brown, Franz R. Villaruel, Diana Segal & Nadia Chaudhri. (2022) Learning processes in relapse to alcohol use: lessons from animal models. Psychopharmacology 240:3, pages 393-416.
Crossref
Crossref
Octavian Vasiliu. (2022) Third-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: What is the evidence?. Frontiers in Psychiatry 13.
Crossref
Crossref
Pascal Valentin Fischler, Michael Soyka, Erich Seifritz & Jochen Mutschler. (2022) Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review. Frontiers in Pharmacology 13.
Crossref
Crossref
Julianne L. Price, Marsha E. Bates, Anthony P. Pawlak, Sarah Grace Uhouse, Sabrina M. Todaro, Julie Morgano & Jennifer F. Buckman. (2022) Use and perceived usefulness of a just-in-time resonance breathing intervention adjunct for substance use disorder: Contextual and physiological predictors. Frontiers in Psychiatry 13.
Crossref
Crossref
Giovanni Martinotti, Stefania Chiappini, Alessio Mosca, Andrea Miuli, Maria Chiara Santovito, Mauro Pettorruso, Valentin Skryabin, Stefano L. Sensi & Massimo Di Giannantonio. (2022) Atypical Antipsychotic Drugs in Dual Disorders: Current Evidence for Clinical
Practice. Current Pharmaceutical Design 28:27, pages 2241-2259.
Crossref
Crossref
Laura Orsolini, Silvia Bellagamba, Virginio Salvi & Umberto Volpe. (2022) A case report of clozapine-treatment-resistant schizophrenia successfully managed with brexpiprazole combination therapy. Asian Journal of Psychiatry 72, pages 103121.
Crossref
Crossref
Pavel Mohr, Jirí Masopust & Miloslav Kopeček. (2022) Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?. Frontiers in Psychiatry 12.
Crossref
Crossref
Mariangela Corbo, Giovanni Martinotti, Andrea Aguglia, Virginio Salvi, Andrea Amerio, Salvatore Calò, Laura Fusar‐Poli, Gianluca Serafini, Maria Signorelli, Mario Amore, Claudio Mencacci, Guido Di Sciascio, Giovanni Biggio, Eugenio Aguglia & Massimo Di Giannantonio. (2021) Long‐acting second‐generation and oral antipsychotics for substance use disorders and psychotic symptoms: Prescribing attitudes among Italian psychiatrists. Perspectives in Psychiatric Care 57:4, pages 1700-1706.
Crossref
Crossref
Matheus Libarino-Santos, Nina R.N. Brandão, Áurea L.N. Borges, Alexia Anjos-Santos, Elisângela G. Cata-Preta, Thaísa Barros-Santos, Daniella Oliveira-Campos, Ana Carolina L. Brito, Thaynara S. Oliveira, Natali D. Kisaki, Aline A.F. Silva, Fabio C. Cruz, Laís F. Berro, Eduardo A.V. Marinho & Alexandre J. Oliveira-Lima. (2021) Aripiprazole and topiramate, alone or in combination, block the expression of ethanol-induced conditioned place preference in mice. Drug and Alcohol Dependence 220, pages 108520.
Crossref
Crossref
Linh-Chi Nguyen, Timothy C. Durazzo, Candice L. Dwyer, Andrew A. Rauch, Keith Humphreys, Leanne M. Williams & Claudia B. Padula. (2020) Predicting relapse after alcohol use disorder treatment in a high-risk cohort: The roles of anhedonia and smoking. Journal of Psychiatric Research 126, pages 1-7.
Crossref
Crossref
Deepak Chouhan, Ankit Uniyal, Anagha Gadepalli, Akhilesh, Vineeta Tiwari, Somesh Agrawal, Tapas Kumar Roy, Sneha Shaw, Narendra Purohit & Vinod Tiwari. (2020) Probing the Manipulated Neurochemical Drive in Alcohol Addiction and Novel Therapeutic Advancements. ACS Chemical Neuroscience 11:9, pages 1210-1217.
Crossref
Crossref
Nestor Szerman, Ignacio Basurte-Villamor, Pablo Vega, Jose Martinez-Raga, Carlos Parro-Torres, Julia Cambra Almerge, Lara Grau-López, Mario De Matteis & Francisco Arias. (2020) Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study. Drugs - Real World Outcomes 7:1, pages 75-83.
Crossref
Crossref
Santosh Kumar Prajapati, Shubham Bhaseen, Sairam Krishnamurthy & Alakh N. Sahu. (2020) Neurochemical Evidence of Preclinical and Clinical Reports on Target-Based Therapy in Alcohol Used Disorder. Neurochemical Research 45:2, pages 491-507.
Crossref
Crossref
Giovanni Martinotti, Andrea Miuli, Mauro Pettorruso, Hamed Ekhtiari, Colleen A. Hanlon, Primavera A. Spagnolo & Massimo Di Giannantonio. 2020. Non Invasive Brain Stimulation in Psychiatry and Clinical Neurosciences. Non Invasive Brain Stimulation in Psychiatry and Clinical Neurosciences
263
282
.
Marianne Destoop, Manuel Morrens, Violette Coppens & Geert Dom. (2019) Addiction, Anhedonia, and Comorbid Mood Disorder. A Narrative Review. Frontiers in Psychiatry 10.
Crossref
Crossref
Samuel R. Chamberlain & Jon E. Grant. (2019) Efficacy of Pharmacological Interventions in Targeting Decision-Making Impairments across Substance and Behavioral Addictions. Neuropsychology Review 29:1, pages 93-102.
Crossref
Crossref
N. N. Ivanets, M. A. Vinnikova, E. V. Ezhkova, M. S. Titkov & R. A. Bulatova. (2019) Aripiprazole and quetiapine in the treatment of patients with 'dual diagnosis' of schizophrenia and drug addiction. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 119:9, pages 52.
Crossref
Crossref
Domenico De Berardis, Michele Fornaro, Annalisa Anastasia, Federica Vellante, Alessandro Valchera, Marilde Cavuto, Giampaolo Perna, Marco Di Nicola, Gianluca Serafini, Alessandro Carano, Maurizio Pompili, Laura Orsolini, Carmine Tomasetti, Gabriella Di Emidio, Giovanni Martinotti & Massimo Di Giannantonio. 2019. Treatment Resistance in Psychiatry. Treatment Resistance in Psychiatry
349
367
.
Maurice Dematteis & Lucie Pennel. (2018) Du produit à la fonction : soins complexes en addictologie par une approche dimensionnelle fonctionnelle. Annales Médico-psychologiques, revue psychiatrique 176:8, pages 758-765.
Crossref
Crossref
Carolina L Haass-Koffler, Kimberly Goodyear, William H Zywiak, Lorenzo Leggio, George A Kenna & Robert M Swift. (2018) Comparing and Combining Topiramate and Aripiprazole on Alcohol-Related Outcomes in a Human Laboratory Study. Alcohol and Alcoholism 53:3, pages 268-276.
Crossref
Crossref
Giovanni Martinotti, Rita Santacroce, Mauro Pettorruso, Chiara Montemitro, Maria Spano, Marco Lorusso, Massimo di Giannantonio & Arturo Lerner. (2018) Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives. Brain Sciences 8:3, pages 47.
Crossref
Crossref
Carmen Gimeno, Marisa Luisa Dorado, Carlos Roncero, Nestor Szerman, Pablo Vega, Vicent Balanzá-Martínez & F. Javier Alvarez. (2017) Treatment of Comorbid Alcohol Dependence and Anxiety Disorder: Review of the Scientific Evidence and Recommendations for Treatment. Frontiers in Psychiatry 8.
Crossref
Crossref
Raymond F. Anton, Joseph P. Schacht, Konstantin E. Voronin & Patrick K. Randall. (2017) Aripiprazole Suppression of Drinking in a Clinical Laboratory Paradigm: Influence of Impulsivity and Self‐Control. Alcoholism: Clinical and Experimental Research 41:7, pages 1370-1380.
Crossref
Crossref
Benjamin Rolland & Mickaël Naassila. (2017) Binge Drinking: Current Diagnostic and Therapeutic Issues. CNS Drugs 31:3, pages 181-186.
Crossref
Crossref
Pedro Damian Gargoloff, Ricardo Corral, Luis Herbst, Miguel Marquez, Giovanni Martinotti & Pedro Rafael Gargoloff. (2016) Effectiveness of agomelatine on anhedonia in depressed patients: an outpatient, open-label, real-world study. Human Psychopharmacology: Clinical and Experimental 31:6, pages 412-418.
Crossref
Crossref